Home
overview

Access to samples is paramount to scientific research. DNA, RNA, proteins, cells and tissues of all types are being stored centrally for later use in experiments conducted by academia and industry alike. This has given rise to the concept of Biobanking, which in 2009 was described by Time Magazine as one of the ’10 Ideas Changing the World Right Now’.

 

Although not an entirely new conception, there is significant change driving current development. With greater impetus being put on data sharing, interoperability and harmonisation of biobanks, single centre research facilities are evolving into research infrastructures. Considering that sharing, storing and using biosamples can vary wildly in cost, social and scientific impact there are efforts now being made to associate value to existing biological resources.
 

Comments from last years delegates included:

'Well planned, great venue, good range of attendees'
'Very Informative; I wish I had attended years ago'
 

SMi’s 2nd annual Biobanking event will reflect the significant change driving current development in biosample management. There will be efforts to associate value to existing biological resources and coverage of important issues experienced by those who donate, manage and expend biobank samples. Focussing on the properties of data sharing and greater involvement between biobanks, allow Biobanking 2012 to give you the most recent up to date information on biobanking today.

• Determine the significance of the Bio Resource Impact Factor (BRIF)
• Examine quality control and quality assurance practices
• Discover how biobanks are used in drug discovery
• Explore technologies for managing biobanks
• Find out why room temperature storage is better than cryogenics
• Communicate between academia and industry over access to samples
• Discuss obstacles to people donating tissue for biomedical research
• Reveal challenges facing new biobanks and building sustainability
 

Heads of Department, Directors, Managers, Team Leaders Researchers and Scientists from:
Research and Development
Supply Chain
Translational science
Population based biobanks
Disease based biobanks
Hospital Trusts
Research Institutes
sample Managers
Tecnology Transfer
Bioinnovation
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Julie Corfield

Julie Corfield, Director, Areteva

9:10 Next generation biobanking: rise of the networks

Martin Yuille

Martin Yuille, Joint Director, Centre for Integrated Genomic Medical Research, University of Manchester

  • Primary biobanks and secondary biobanks
  • Networked biobanks and networked biobanking
  • The emergence of the science of biobanking
  • 9:50 The road to harmonization of biospecimen practices in the U.S. and internationally

    Helen Moore

    Helen Moore, Director of Biospecimen Research Network (BRN), Office of Biorepositories and Biospecimen Research (OBBR), National Cancer Institute

  • Ethical, legal, scientific, IT, and operational challenges to harmonization
  • The NCI Best Practices for Biospecimen Resources
  • Biospecimen Science research programs in the U.S. and Europe
  • Building evidence-based Best Practices
  • Acquisition of normal tissues for genomic research
  • 10:30 Morning Coffee

    10:50 Challenges facing new biobanks and building sustainability

    Geraldine Thomas

    Geraldine Thomas, Chair in Molecular Pathology, Chernobyl Tissue Bank

  • Sample acquisition strategies
  • Appealing to donation candidates
  • Methods for sample storage
  • Cost recovery, why the taboo?
  • 11:30 Coordinating national biobanking projects

    Kristian  Hveem

    Kristian Hveem, Head of HUNT Biobank, Leader Biobank Norway, Norwegian University Of Science And Technology

  • The role of genetic factors, environmental exposures and lifestyle in major diseases of late and middle age
  • Collecting extensive data and biological samples
  • The relationship between how samples are processed and scientific usefulness
  • Sample handling and storage protocol
  • 12:10 Panel discussion: ‘How can biobanking be made more cost effective?’

  • Cost recovery, what can be done?
  • Managerial issues
  • Budgeting and financial strategy
  • Public sector services and reflective reimbursement
  • Pablo Arrisi

    Pablo Arrisi, Biosample Operations Manager, Roche Products

    Geraldine Thomas

    Geraldine Thomas, Chair in Molecular Pathology, Chernobyl Tissue Bank

    Martin Yuille

    Martin Yuille, Joint Director, Centre for Integrated Genomic Medical Research, University of Manchester

    George   Tokiwa

    George Tokiwa, Associate Scientific Director, Merck Research Laboratories

    Paul Hofman

    Paul Hofman, Head of Human Biobank Unit, Pasteur Hopital, University of Nice

    12:50 Networking Lunch

    13:50 The Proposed EU Data Protection Regulation - Impact on Biobanks

    Kristof Van Quathem

    Kristof Van Quathem, Associate , Covington & Burling Llp

  • New features of European Commission proposed regulation replacing national data protection laws such as the data protection act
  • New features including breach notification obligation, explicit reearch exemption and new rules on international transfers and applicable law.
  • How will the proposed regulation impact the use of personal data stored and shared in Biobanks - Will ICFs have to be modified and in what respect?
  • Secondary use of samples and associated data, and impact of key-coding personal data under the new regime.
  • 14:30 The Roche clinical repository - key enabler to personalized healthcare

    Pablo Arrisi

    Pablo Arrisi, Biosample Operations Manager, Roche Products

  • PHC and Biomarkers
  • Operations behind biosampling in clinical trials
  • RCR: the facility and associated processes
  • 15:10 Building a large-scale biobank for Sweden

    Anders  Brinne

    Anders Brinne, Biobank Informatics Manager, Karolinska Institutet

  • Supporting large-scale prospective sample- and data collection 
  • Local vs central sample management
  • Making use of healthcare infrastructure
  • Securing personal integrity
  • 15:50 Afternoon Tea

    16:10 Quality control of biological samples

    John Cason

    John Cason, Director of the Infectious Diseases BioBank, Kings College London

  • Sample handling and storage protocol
  • Preservation techniques
  • Temperature monitoring, stabilisation and validation
  • 16:30 Environmental monitoring Biobanking facilities

    Pete Jackson

    Pete Jackson, MD, ELPRO UK

  • Why do we need to monitor
  • Where do we need to monitor - location, position and quality of sensors
  • What needs to be monitored
  • Specific challenges within a biobank
  • Keep the overview - Optimise your processes
  • Requirements of a monitoring system
  • Typical project handling
  • Building in security
  • Approaches for automating the handling of data
  • Approaches for maintaining the system with minimal disruption
  • Validation
  • 17:10 Quality assurance and integrated biosample processing management

    George   Tokiwa

    George Tokiwa, Associate Scientific Director, Merck Research Laboratories

  • Quality control, is there any point without quality assurance?
  • Considerations for managing the planning, collection and processing of clinical specimens
  • Methods to ensure quality from protocol drafting to specimen disposition
  • Considerations for metrics
  • 17:50 Technologies for managing biobanks with a focus on Radio Frequency Identification (RFID)

    Paul Hofman

    Paul Hofman, Head of Human Biobank Unit, Pasteur Hopital, University of Nice

  • Advantages of RFID based systems
  • Improving traceability and security
  • Tracking from bank to lab
  • 18:30 Chairman’s Closing Remarks and Close of Day One

    Julie Corfield

    Julie Corfield, Director, Areteva

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Julie Corfield

    Julie Corfield, Director, Areteva

    9:10 Strategic Tissue Repository Alliances Through Unified Methods (STRATUM)

    Julie Corfield

    Julie Corfield, Director, Areteva

  • The foundation for a biobanking infrastructure in the UK
  • What it aims to achieve and why; including
  • Biobanking Policy
  • Technical Standards and Sample Life Cycle Management
  • Optimising access to and use of samples
  • 9:45 “For the Times they are A-Changin’”: Assessing the Ethical and Legal Issues of Biobank Closure

    Man H Zawati

    Man H Zawati , Lawyer and Academic Associate , McGill University Department of Human Genetics

  • Associated ethical issues with sample reallocation
  • Gaining consent for closure plans
  • Maximising use while maintaining trust
  • 10:20 Morning Coffee

    10:50 Informed vs. standardised consent the ethical implications

    Balwir Matharoo-Ball

    Balwir Matharoo-Ball, Operations Manager Trasitional Research & Biobanking, Nottingham University Hospital NHS Trust

  • Gaining broad consent
  • Attaining clinical phenotype data
  • Maintaining confidentiality
  • Access to information
  • 11:25 The LifeGene story so far

    Jens  Mattsson

    Jens Mattsson, CEO, Lifegene Project

  • It is a national Swedish prospective cohort representing an infrastructure for research into diseases, with a lifespan approach starting with those that have their onset early and in midlife
  • It has a number of features making it unique, e.g. household based sampling, omics-ready biomaterial and the first study of children with complete pre- and perinatal data from both the mother and father
  • It takes advantage of Swedish strong ICT position and state of the art biobanking facilities
  • Researchers from Sweden and abroad can apply equally to withdraw phenotypic data and bio-specimens.
  • 12:00 Panel Discussion: ‘Public engagement barriers: obstacles to people donating tissue for biomedical research’

  • Developments in information technologies
  • The phantom Public
  • The ethics of passing on genomic data
  • Are there barriers?
  • Are the barriers due to processes or people?
  • Man H Zawati

    Man H Zawati , Lawyer and Academic Associate , McGill University Department of Human Genetics

    Celine  Lewis

    Celine Lewis, Public Engagement Lead STRATUM, Genetic Alliance

    Katherine Littler

    Katherine Littler, Policy Adviser, Welcome Trust

    12:35 Networking Lunch

    13:35 Biobanking in drug discovery

    Mads Roepke

    Mads Roepke, Scientist, Leo Pharma

  • How many samples pharmaceutical companies require for each phase of research
  • Sample type (e.g. frozen -80°c)
  • Clinical data required
  • 14:10 Where are my samples? Supply chain informatics in pre-competitive translational research

    Anthony Rowe

    Anthony Rowe, Principal Research Scientist, External Innovation R&D IT, Janssen

     

    ·          Pre-competitive research and translational studies
    ·          Underlying biology of complex disease and multiple research organisations
    ·          A new class of infrastructure to manage the flow of samples and information
    ·          Issues and risks of managing the logistics of samples beyond the walls of a biobank

    14:45 Promoting the availability and maximising the value from UCLs many biospecimen collections with Tissue Access for Patient Benefit

  • Promoting the availability and maximising the value from UCL’s many biospecimen collections
  • Physical Biobanks at UCL - UCL-RFH Biobank and UCL/UCLH Biobank for studying health and disease
  • Challenges and experiences of setting up centralised infrastructure
  • Amir Gander

    Amir Gander, Senoir Knowledge Transfer Associate, UCL Medical School Royal Free Campus

    Kirstin Goldring

    Kirstin Goldring, Biobank Facilitator, University College London

    15:20 Afternoon Tea

    15:50 From bench to clinic: the importance of healthy and diseased human tissue in discovering new therapeutics for respiratory disease

    Paul Whittaker

    Paul Whittaker, Direstor and Unit Head for Pre-Clinical Biomarkers, Respiratory Disease Area, Novartis

    • Human tissue is a crucial element in the discovery and validation of new targets and biomarkers
    • The need for tissue from well-phenotyped patient cohorts
    • Human tissue is a key link between animal model experiments and clinical trials
    • What do we need?
    • How much do we need?

    16:25 The significance of the bio resource impact factor

    Raymond Dalgleish

    Raymond Dalgleish, Senior Lecturer, University of Leicester

  • The main objective of proposing a Bioresource Research Impact Factor (BRIF)
  • Cataloguing bioresource data access and sharing policies
  • The need for bioresources to be identified by a unique digital identifier
  • Specific requirements for citing bioresources
  • 17:00 How can biobanks contribute to Stratified Medicines?

    Martyn Foster

    Martyn Foster, Independent Consultant in Experimental Pathology, Independent Consultancy

  • The vision and key issues for stratified medicines research
  • The problem of ‘pathology phenotype’ versus ‘clinical phenotype’
  • Biobank sample collection: ‘opportunity-driven’ versus ‘event-driven’ versus ‘hypothesis-driven’
  • Interrogating the biobank: an iterative process
  • Case study: histopathology biobanks in COPD target validation and patient stratification
  • 17:35 Chairman’s Closing Remarks and Close of Day Two

    Julie Corfield

    Julie Corfield, Director, Areteva

    +

    FEATURED SPEAKERS

    Amir Gander

    Amir Gander

    Senoir Knowledge Transfer Associate, UCL Medical School Royal Free Campus
    George   Tokiwa

    George Tokiwa

    Associate Scientific Director, Merck Research Laboratories
    Pablo Arrisi

    Pablo Arrisi

    Biosample Operations Manager, Roche Products
    Paul Whittaker

    Paul Whittaker

    Direstor and Unit Head for Pre-Clinical Biomarkers, Respiratory Disease Area, Novartis

    Amir Gander

    Senoir Knowledge Transfer Associate, UCL Medical School Royal Free Campus
    Amir Gander

    Anders Brinne

    Biobank Informatics Manager, Karolinska Institutet
    Anders  Brinne

    Ann Cooreman

    Chief operating officer, Tissue Solutions
    Ann Cooreman

    Balwir Matharoo-Ball

    Operations Manager Trasitional Research & Biobanking, Nottingham University Hospital NHS Trust
    Balwir Matharoo-Ball

    Brian Thompson

    Director of R&D, Nottingham University Hospital NHS Trust
    Brian Thompson

    Celine Lewis

    Public Engagement Lead STRATUM, Genetic Alliance
    Celine  Lewis

    Daniel Cooper

    Partner , Covington & Burling Llp
    Daniel Cooper

    George Tokiwa

    Associate Scientific Director, Merck Research Laboratories
    George   Tokiwa

    Geraldine Thomas

    Chair in Molecular Pathology, Chernobyl Tissue Bank
    Geraldine Thomas

    Helen Moore

    Director of Biospecimen Research Network (BRN), Office of Biorepositories and Biospecimen Research (OBBR), National Cancer Institute
    Helen Moore

    Hemal Rajani

    Technical Project Manager, Labvantage Solutions
    Hemal Rajani

    Jens Mattsson

    CEO, Lifegene Project
    Jens  Mattsson

    John Cason

    Director of the Infectious Diseases BioBank, Kings College London
    John Cason

    Julie Corfield

    Director, Areteva
    Julie Corfield

    Katherine Littler

    Policy Adviser, Welcome Trust
    Katherine Littler

    Kirstin Goldring

    Biobank Facilitator, University College London
    Kirstin Goldring

    Kristian Hveem

    Head of HUNT Biobank, Leader Biobank Norway, Norwegian University Of Science And Technology
    Kristian  Hveem

    Kristof Van Quathem

    Associate , Covington & Burling Llp
    Kristof Van Quathem

    Mads Roepke

    Scientist, Leo Pharma
    Mads Roepke

    Man H Zawati

    Lawyer and Academic Associate , McGill University Department of Human Genetics
    Man H Zawati

    Martin Yuille

    Joint Director, Centre for Integrated Genomic Medical Research, University of Manchester
    Martin Yuille

    Martyn Foster

    Independent Consultant in Experimental Pathology, Independent Consultancy
    Martyn Foster

    Neil Formstone

    Lay Member, NIHR Biomedical Research Centre
    Neil Formstone

    Pablo Arrisi

    Biosample Operations Manager, Roche Products
    Pablo Arrisi

    Paul Hofman

    Head of Human Biobank Unit, Pasteur Hopital, University of Nice
    Paul Hofman

    Paul Whittaker

    Direstor and Unit Head for Pre-Clinical Biomarkers, Respiratory Disease Area, Novartis
    Paul Whittaker

    Pete Jackson

    MD, ELPRO UK
    Pete Jackson

    Raymond Dalgleish

    Senior Lecturer, University of Leicester
    Raymond Dalgleish

    Workshops

    Virtual Biobanking: interactive workshop and practical tips
    Workshop

    Virtual Biobanking: interactive workshop and practical tips

    Copthorne Tara Hotel
    10th July 2012
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.